Amgen preps for key investor meeting

Sitting on $17 billion, Amgen ($AMGN) is bracing for a tense meeting with investors who want to see what the big biotech will do with its cache of cash--and whether it has anything in the pipeline that can soon follow the successful path carved out by its bone drug denosumab. Report